Table 1 Demographic characteristics of participants in qualitative interviews and on-line survey
Characteristics | Qualitative Phase (n = 16) | Quantitative Phase (n = 90) |
|---|---|---|
Recruitment source (n, %) | ||
IPF panels | 16 (100) | 46 (51) |
Advocacy/Support Groups | 0 (0) | 44 (49) |
Sex (n, %) | ||
Male | 6 (38) | 47 (52) |
Female | 10 (62) | 43 (48) |
Age | ||
Median (Range) | 69 (48–76) | 72 (41–91) |
Years since IPF diagnosis | ||
Median (Range) | 5 (12) | 4 (13) |
Site of Care (n, %) | ||
Expert IPF or interstitial lung disease (ILD) center of excellence (i.e., affiliated with a university) | NA | 45 (50) |
Community private practice/doctors'office | NA | 41 (46) |
Unsure | NA | 4 (4) |
Area of residence (n, %) | ||
Urban/Suburban | NA | 64 (71) |
Rural | NA | 26 (29) |
Geographic region (n, %) | ||
Northeast | 4 (25) | 14 (16) |
Mid-Atlantic or Southeast | 5 (31) | 27 (30) |
Midwest | 3 (19) | 24 (27) |
Western US | 4 (25) | 25 (27) |
Smoking status (n, %) | ||
Current smoker | NA | 4 (4) |
Previous smoker | NA | 49 (54) |
Never smoker | NA | 37 (41) |
Antifibrotic exposure (n, %) | ||
Pirfenidone alone | 6 (38) | 21 (23) |
Nintedanib alone | 5 (31) | 29 (32) |
Both pirfenidone and nintedanib via switch | 3 (19) | 9 (10) |
Never on antifibrotic | 2 (13) | 31 (34) |
Insurance (n, %) | ||
Medicare | 12 (75) | 62 (69) |
Medicaid | 0 (0) | 5 (6) |
Commercial | 4 (25) | 17 (19) |
Veterans Administration/TriCare | 0 (0) | 2 (2) |
Ethnicity (n, %) | ||
White or Caucasian | NA | 80 (89) |
Black or African American | NA | 3 (3) |
Native American/American Indian or Alaskan Native | NA | 2 (2) |
Asian, Native Hawaiian or Other Pacific Islander | NA | 1 (1) |
Hispanic | NA | 2 (2) |
More than one race/ethnicity | NA | 2 (2) |
Education (n, %) | ||
No high school diploma | NA | 1 (1) |
High school/Equivalent | NA | 30 (33) |
College degree | NA | 36 (40) |
Advanced degree | NA | 23 (26) |
Supplemental oxygen use (n, %) | ||
Yes | 14 (88) | 49 (54) |
No | 2 (13) | 41 (46) |